| Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer (NCT03775265) | National Cancer Institute (NCI) | 2019-06-03 |
| M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (NCT03517969) | National Cancer Institute (NCI) | 2019-05-29 |
| Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT03745352) | National Cancer Institute (NCI) | 2019-05-20 |
| Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT03813147) | National Cancer Institute (NCI) | 2019-05-17 |
| Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients (NCT03745326) | National Cancer Institute (NCI) | 2019-05-16 |
| Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer (NCT03300544) | National Cancer Institute (NCI) | 2019-05-14 |
| Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors (NCT03866382) | National Cancer Institute (NCI) | 2019-05-13 |
| Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia (NCT03739814) | National Cancer Institute (NCI) | 2019-05-08 |
| Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery (NCT03604991) | National Cancer Institute (NCI) | 2019-05-03 |
| Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer (NCT03348631) | National Cancer Institute (NCI) | 2019-05-01 |
| Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma (NCT03528642) | National Cancer Institute (NCI) | 2019-05-01 |
| Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer (NCT03860987) | National Cancer Institute (NCI) | 2019-04-30 |
| Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma (NCT03922724) | National Cancer Institute (NCI) | 2019-04-18 |
| Children and Adults With Chordoma (NCT03910465) | National Cancer Institute (NCI) | 2019-04-16 |
| Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement (NCT03724084) | National Cancer Institute (NCI) | 2019-04-10 |
| Natural History Study of Children and Adults With Fibrolamellar Hepatocellular Carcinoma (NCT03748927) | National Cancer Institute (NCI) | 2019-04-08 |
| Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer (NCT03793179) | National Cancer Institute (NCI) | 2019-04-05 |
| Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer (NCT03199885) | National Cancer Institute (NCI) | 2019-04-05 |
| Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial (NCT03728881) | National Cancer Institute (NCI) | 2019-04-01 |
| Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy (NCT03701308) | National Cancer Institute (NCI) | 2019-03-28 |
| Men at High Genetic Risk for Prostate Cancer (NCT03805919) | National Cancer Institute (NCI) | 2019-03-27 |
| Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype (NCT03718767) | National Cancer Institute (NCI) | 2019-03-27 |
| Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment (NCT03531827) | National Cancer Institute (NCI) | 2019-03-26 |
| Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy (NCT03382574) | National Cancer Institute (NCI) | 2019-03-14 |
| Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1 (NCT03830229) | National Cancer Institute (NCI) | 2019-03-13 |
| Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (NCT03786783) | National Cancer Institute (NCI) | 2019-03-04 |
| Sunitinib in Sarcomas of the Central Nervous System (NCT03641326) | National Cancer Institute (NCI) | 2019-02-21 |
| A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma (NCT03698019) | National Cancer Institute (NCI) | 2019-02-15 |
| A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer (NCT03803761) | National Cancer Institute (NCI) | 2019-02-13 |
| Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia (NCT03701282) | National Cancer Institute (NCI) | 2019-02-12 |
| Confocal Endoscopic Microscopy for Detection of Early Stage Gastric Cancer in Subjects With Hereditary Diffuse Gastric Cancer Syndrome (NCT03648879) | National Cancer Institute (NCI) | 2019-02-11 |
| Online Survey in Studying Smoking Attitudes and Behaviors Among Current Smokers (NCT03863795) | National Cancer Institute (NCI) | 2019-02-04 |
| Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis (NCT03317392) | National Cancer Institute (NCI) | 2019-02-04 |
| Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia (NCT03737981) | National Cancer Institute (NCI) | 2019-01-31 |
| Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations (NCT03212274) | National Cancer Institute (NCI) | 2019-01-30 |
| Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 (NCT03284385) | National Cancer Institute (NCI) | 2019-01-29 |
| Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children and Young Adults With High Grade or High-Risk Cancer and Their Caregivers (NCT03538587) | National Cancer Institute (NCI) | 2019-01-29 |
| Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors (NCT03739827) | National Cancer Institute (NCI) | 2019-01-28 |
| Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT03701321) | National Cancer Institute (NCI) | 2019-01-25 |
| Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer (NCT03827343) | National Cancer Institute (NCI) | 2019-01-23 |
| The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females (NCT03436745) | National Cancer Institute (NCI) | 2019-01-22 |
| Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer (NCT03598257) | National Cancer Institute (NCI) | 2019-01-18 |
| AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification (NCT03253679) | National Cancer Institute (NCI) | 2019-01-16 |
| Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma (NCT03027388) | National Cancer Institute (NCI) | 2019-01-09 |
| A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) (NCT03595124) | National Cancer Institute (NCI) | 2019-01-08 |
| Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer (NCT03738228) | National Cancer Institute (NCI) | 2019-01-07 |
| Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations (NCT03794297) | National Cancer Institute (NCI) | 2019-01-04 |
| Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas (NCT03038672) | National Cancer Institute (NCI) | 2018-12-21 |
| Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer (NCT03602586) | National Cancer Institute (NCI) | 2018-12-21 |
| M7824 in People With Recurrent Respiratory Papillomatosis (NCT03707587) | National Cancer Institute (NCI) | 2018-12-19 |
| Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma (NCT03644550) | National Cancer Institute (NCI) | 2018-12-04 |
| Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer (NCT03600701) | National Cancer Institute (NCI) | 2018-11-29 |
| Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors (NCT03598244) | National Cancer Institute (NCI) | 2018-11-27 |
| Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial (NCT03712605) | National Cancer Institute (NCI) | 2018-11-15 |
| Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) (NCT03698994) | National Cancer Institute (NCI) | 2018-11-14 |
| Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations (NCT03581292) | National Cancer Institute (NCI) | 2018-11-06 |
| 5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors (NCT03366116) | National Cancer Institute (NCI) | 2018-11-05 |
| Optimization of Collection Methods for Studies of the Human Microbiota (NCT03731702) | National Cancer Institute (NCI) | 2018-11-01 |
| Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery (NCT03317405) | National Cancer Institute (NCI) | 2018-10-31 |
| Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors (NCT03375320) | National Cancer Institute (NCI) | 2018-10-26 |
| Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (NCT03309878) | National Cancer Institute (NCI) | 2018-10-24 |
| Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1(NF1) on Clinical Treatment Trials (NCT03531814) | National Cancer Institute (NCI) | 2018-10-23 |
| Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H) (NCT06400238) | National Cancer Institute (NCI) | 2018-10-15 |
| Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT03587311) | National Cancer Institute (NCI) | 2018-10-12 |
| Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G) (NCT06360588) | National Cancer Institute (NCI) | 2018-10-08 |
| Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma (NCT03126630) | National Cancer Institute (NCI) | 2018-10-04 |
| Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone (NCT03660826) | National Cancer Institute (NCI) | 2018-09-27 |
| Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia (NCT03289910) | National Cancer Institute (NCI) | 2018-09-24 |
| PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery (NCT03218826) | National Cancer Institute (NCI) | 2018-09-24 |
| Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (NCT03321643) | National Cancer Institute (NCI) | 2018-09-18 |
| T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma (NCT03602612) | National Cancer Institute (NCI) | 2018-09-14 |
| M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers (NCT03554473) | National Cancer Institute (NCI) | 2018-09-11 |
| Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia (NCT03190915) | National Cancer Institute (NCI) | 2018-09-09 |
| Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer (NCT03412877) | National Cancer Institute (NCI) | 2018-09-06 |
| Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation (NCT03663933) | National Cancer Institute (NCI) | 2018-09-04 |
| Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1) (NCT06308822) | National Cancer Institute (NCI) | 2018-08-20 |
| DoD-NCI TRICARE Feasibility Study (NCT02339025) | National Cancer Institute (NCI) | 2018-08-18 |
| Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma (NCT03502733) | National Cancer Institute (NCI) | 2018-08-14 |
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) (NCT03526250) | National Cancer Institute (NCI) | 2018-08-13 |
| Defined Green Tea Catechin Extract in Preventing Liver Cancer in Participants With Cirrhosis (NCT03278925) | National Cancer Institute (NCI) | 2018-08-09 |
| Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer (NCT03377101) | National Cancer Institute (NCI) | 2018-08-07 |
| Optimal Methods of Disease Detection in Children and Young Adults With Acute Lymphoblastic Leukemia in the Pediatric Oncology Branch (NCT03627208) | National Cancer Institute (NCI) | 2018-08-02 |
| Dolcanatide in Preventing Colorectal Cancer in Healthy Volunteers (NCT03300570) | National Cancer Institute (NCI) | 2018-07-27 |
| Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines (NCT03481816) | National Cancer Institute (NCI) | 2018-07-24 |
| Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer (NCT03237780) | National Cancer Institute (NCI) | 2018-07-20 |
| Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma (NCT03228537) | National Cancer Institute (NCI) | 2018-07-16 |
| Olaparib in People With Malignant Mesothelioma (NCT03531840) | National Cancer Institute (NCI) | 2018-07-11 |
| Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer (NCT03107780) | National Cancer Institute (NCI) | 2018-07-09 |
| Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy (NCT03253744) | National Cancer Institute (NCI) | 2018-07-05 |
| Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer (NCT03233711) | National Cancer Institute (NCI) | 2018-07-05 |
| Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2) (NCT06351371) | National Cancer Institute (NCI) | 2018-07-03 |
| Extended Follow-up of Women Who Received One, Two, and Three Doses of the HPV Vaccine in the Costa Rica Vaccine Trial (CVT), ESCUDDO-CVT Study (NCT03309033) | National Cancer Institute (NCI) | 2018-07-02 |
| Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases (NCT02971501) | National Cancer Institute (NCI) | 2018-06-27 |
| Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F) (NCT05490771) | National Cancer Institute (NCI) | 2018-06-20 |
| Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma (NCT03217266) | National Cancer Institute (NCI) | 2018-06-20 |
| IFNL4 Genotype for Predicting Response to Ledipasvir/Sofosbuvir (NCT03639207) | National Cancer Institute (NCI) | 2018-06-15 |
| Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer (NCT03323658) | National Cancer Institute (NCI) | 2018-06-15 |
| Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma (NCT03031730) | National Cancer Institute (NCI) | 2018-06-14 |
| Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma (NCT03304639) | National Cancer Institute (NCI) | 2018-06-12 |
| Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG) (NCT03258593) | National Cancer Institute (NCI) | 2018-06-07 |